• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice

    2016-12-01 09:23:41ChengyouZhengBaojianGuoWeiCaiWeiCuiShinghungMakYuqiangWangSimonMingyuenLeeYifanHanZaijunZhangInstituteofNewDrugResearchandGuangzhouKeyLaboratoryofInnovativeChemicalDrugResearchinCardiocerebrovascularDiseasesJinan

    Cheng-you Zheng, Bao-jian Guo, Wei Cai, Wei Cui, Shing-hung Mak, Yu-qiang Wang, Simon Ming-yuen Lee, Yi-fan Han,, Zai-jun Zhang, Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region, China State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao Special Administrative Region, China

    No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice

    Cheng-you Zheng1, Bao-jian Guo1, Wei Cai1, Wei Cui2, Shing-hung Mak3, Yu-qiang Wang1, Simon Ming-yuen Lee4, Yi-fan Han3,*, Zai-jun Zhang1,*
    1 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China
    2 School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China
    3 Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region, China
    4 State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao Special Administrative Region, China

    How to cite this article: Zheng CY, Guo BJ, Cai W, Cui W, Mak SH, Wang YQ, Lee SMY, Han YF, Zhang ZJ (2016) No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice. Neural Regen Res 11(8)∶1339-1346.

    Funding: This study was supported by grants from the Natural Science Foundation of Guangdong Province of China, No. 2015A030313317; a grant from the Science and Technology Program of Guangzhou City of China, No. 2014J4100097; and partially by a grant from the Science and Technology Development Fund (FDCT) of Macao Special Administrative Region, No. 134/2014/A3; a grant from the Research Committee of University of Macau, No. MYRG139(Y1-L4)-ICMS12-LMY and MYRG2015-00214-ICMS-QRCM; and grants from the Research Grants Council of Hong Kong Special Administrative Region of China, No. 561011, 15101014; the Hong Kong Polytechnic University of China, No. G-SB10, G-UC15 and G-YBGQ.

    Zai-jun Zhang, M.D. or

    Yi-fan Han,

    zaijunzhang@163.com or bcyfhan@polyu.edu.hk.

    orcid:

    0000-0002-0690-1673

    (Zai-jun Zhang)

    Accepted: 2016-06-08

    Graphical Abstract

    Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism. By using neurobehavioural tests, high-performance liquid chromatography and western blot assay, we showed that B3C at 0.3 mg/kg, rasagiline at 0.02 mg/kg, as well as co-treatment with B3C and rasagiline prevented MPTP-induced behavioural abnormities, increased the concentrations of dopamine and its metabolites in the striatum, and up-regulated the expression of tyrosine hydroxylase in the substantia nigra. However, the neuroprotective effects of co-treatment were not significantly improved when compared with those of B3C or rasagiline alone. Collectively, we have demonstrated that B3C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects.

    nerve regeneration; Parkinson's disease; bis(propyl)-cognitin; rasagiline; monoamine oxidase B; dopamine; multitarget; synergism; neuroprotection; neural regeneration

    Introduction

    Parkinson’s disease (PD), the second most common neurodegenerative disorder, has emerged as one of the major public health problems worldwide (Jeanjean and Aubert, 2011). Unfortunately, the exact molecular pathology of PD remains to be elucidated. Currently used medications such as dopamine precursor (levodopa), dopamine agonists and monoamine oxidase-B (MAO-B) inhibitors (selegiline and rasagiline), are reported to have modest symptomatic benefits without obvious disease-modifying potential, because their primary target is not dopaminergic neuronal loss (Smith, 2010; Meissner et al., 2011). The ideal PD therapy aims to produce neuroprotective effects, concurrently relieve PD-associated symptoms and delay the loss of dopaminergic neurons in the substantia nigra (Schapira, 2004).

    Rasagiline (Figure 1), a second-generation MAO-B inhibitor, has been approved by US Food and Drug Administration (FDA) for the treatment of PD (Degli Esposti et al., 2015). Rasagiline is reported to produce neuroprotective effects in various experimental models both in vitro and in vivo (Naoi et al., 2013). Interestingly, the neuroprotective effects of rasagiline might be associated with its anti-apoptotic activities rather than its MAO-B inhibition property (Youdim et al., 2001). However, the request for an on-label indication of rasagiline for neuroprotection in PD has been repeatedly denied by FDA, because there is limited evidence to prove its neuroprotective effects in clinical trials (Ahlskog and Uitti, 2010).

    Bis(propyl)-cognitin (B3C; Figure 1), in which two tacrine moieties were linked by three methylene (-CH2-) group, was originally synthesized as a novel acetylcholinesterase (AChE) inhibitor (Carlier et al., 1999). We have previously demonstrated the neuroprotective effects of B3C in various in vivo models of neurodegenerative disorders (Luo et al., 2010; Han et al., 2012). B3C was also reported to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuronal loss and Parkinsonian motor defects in mice (Yao et al., 2012). The neuroprotective effects of B3C are reported to be associated with its AChE inhibition (Carlier et al., 1999), myocyte enhancer factor-2D (MEF2D) enhancement (Yao et al., 2012), as well as uncompetitive N-methyl-D-aspartate receptor antagonism (Luo et al., 2010).

    Considering the multi-factorial etiological nature of PD (Calabresi and Di Filippo, 2015), multiple drug therapy might offer a new hope by addressing complex pathological aspects. The combination of drug molecules with different modes of action could concurrently act on multiple targets and/or biological processes which cause the chronic and progressive neurodegeneration in PD (Reznichenko et al., 2010; Zhang et al., 2015). In the light of this rationale, we investigated whether the post-MPTP loss of dopaminergic neurons could be additively/synergistically restored by a combination of rasagiline and B3C. We also examined whether MPTP-induced behavioral abnormities and biochemcial changes could be reversed by these compounds.

    Materials and Methods

    Ethics statement

    Animal treatment and maintenance were carried out in accordance with the guidelines established by the National Institutes of Health for the Care and Use of Laboratory Animals and were approved by the Ethics Committee of Jinan University in China (Ethical approval No. EAEJNU-2013-0117). Precautions were taken to minimize suffering and the number of animals used in the study.

    Treatments

    Fifty-six specific-pathogen-free male C57BL/6 mice (25 ± 2 g and 7-8 weeks old) were purchased from the Animal Center of Guangdong Province in China (Certification No. SCXK (Yue)-2013-0002). Mice were housed under a 12-hour light/dark cycle, and allowed to acclimate for 7 days before treatment. Mice were randomly divided into seven groups (control, MPTP, MPTP + 0.3 mg/kg B3C, MPTP + 1 mg/kg B3C, MPTP + 0.02 mg/kg rasagiline, MPTP + 0.1 mg/kg rasagiline, and MPTP + 0.3 mg/kg B3C + 0.02 mg/kg rasagiline groups). Mice in the control group received saline (0.1 mL/10 mg). The remaining mice were given MPTP (30 mg/kg/day, Sigma-Aldrich, St. Louis., MO, USA) intraperitoneally once daily for 5 consecutive days to induce Parkinsonism. Resting period (3 days) was allowed for the conversion of MPTP to MPP+(Tatton and Greenwood, 1991). On day 8, B3C (0.3, 1 mg/kg), rasagiline (0.02, 0.1 mg/kg) (Sigma-Aldrich), or B3C (0.3 mg/kg) + rasagiline (0.02 mg/kg) were administered intragastrally once daily for 7 consecutive days according to the grouping. Mice in the control group or the MPTP group received equal volume of saline (0.1 mL/10 mg).

    Behavioral analysis

    On day 15, after final drug treatment, a serial of tests including catalepsy, pole, rotarod and foot-printing tests was used to analyze different aspects of Parkinsonism, such as hypokinetic disorder, rigidity and problem with gait (difficulty in walking). These tests were performed between 9 a.m. and 2 p.m. under normal room lighting. Behavioral experiments were randomized and blinded by an independent researcher.

    The catalepsy test was performed according to a previous publication (Sedelis et al., 2001), by placing the forepaws of mice on a horizontal metal bar (2 mm in diameter), 15 cm above the tabletop. The duration until one of the hind paws caught the metal bar was recorded. The average of duration of three successive trials was measured. Between each trial, animals were allowed to rest for 1 minute.

    The pole test was adapted from Ogawa et al. (1985). The pole test consisted of a 50 cm high steel pole, 0.5 cm in diameter, and wrapped with gauze to prevent slipping and the base position in the home cage. A rubber ball was glued on the top of the pole to prevent animals from sitting on the top and to help position the animals on the pole (by sliding the forepaws over the ball and holding the animal by the tail). The time that animals required to climb down the pole was measured. During pre-training as well as post-MPTP sessions, each animal was subjected to three successive trials,with a 10-minute interval. The average time of three trials was used for statistical analyses.

    Rotarod test was used to measure motor balance and coordination (Bao et al., 2012). Mice were placed on rotating rod with 3 cm diameter (Rotarod for mice, ZH-YLS-4C, Zhenghua, Anhui Province, China). Tested animals were separated by large disks. After the mice were placed on the rod at constant rotational speed of 5 r/min, the trial was started and rotational speed was automatically increased from 5 to 30 r/min within 5 minutes. The trial stopped when the mouse fell down, activating a switch that automatically stopped a timer, or when 5 minutes were completed. Mice were pre-trained on the rotarod for 3 consecutive days before MPTP treatment in order to reach a stable performance. The final test was performed in three sessions with an interval of 30 minutes. Rotarod performances in three sessions were recorded, and the average time on the rotarod was compared among groups.

    For the footprint test, we followed the procedure described by Richter et al. (2007). Mice were first trained to pass straight forward through the wood corridor (5 cm wide, 85 cm long). Then mice with their forepaws with black ink colored and hindpaws with red ink colored were placed into the corridor. Their footsteps were recorded on a white absorbing paper. The duration of mice crossing the corridor was recorded, stride length and step width were also measured. Three trials were carried out and the results were averaged.

    Tissue processing

    After behavioral testing, animals were sacrificed by a 0.5 mL/10 g intraperitoneal injection of 10% chloral hydrate. The tissues of striatum and substantia nigra (Hayley et al., 2004; Jackson-Lewis and Przedborski, 2007) were dissected rapidly on ice and frozen in liquid nitrogen. Tissues were stored at -80°C until processed for high-pressure liquid chromatography (HPLC) or western blot assay.

    Determination of dopamine and its metabolites, homovanilic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels by electrochemical HPLC

    Striatal tissues were used for neurobiochemical analysis by electrochemical HPLC. Briefly, the striatum was weighed, and homogenized in 0.1 M perchloric acid (HClO4) containing 0.01% ethylenediamine tetraacetic acid. The homogenate was centrifuged at the speed of 10,000 × g for 10 minutes at 4°C. The supernatant was filtered through 0.22 μm filter membrane and 20 μL samples were injected into the column. Dopamine and its metabolites (DOPAC and HVA) were analyzed using a HPLC system (Agilent-1200, Wakefield, MA, USA) coupled to a 2465 electrochemical detector (Waters, Milford, MA, USA) as described previously (Zhang et al., 2014). Concentrations of dopamine and its metabolites were expressed as ng/mg tissue.

    Western blot assay

    Tissues from the substantia nigra were homogenized with radioimmunoprecipitation assay lysis buffer containing 1 mM phenylmethylsulfonyl fluoride and 1% protease inhibitor cocktail (Pierce, Rockford, IL, USA) on ice. Lysis was centrifuged at 12,500 × g for 20 minutes at 4°C. The supernatant was separated and the amount of protein was determined using the bicinchoninic acid protein assay kit (Pierce). Protein sample (30 μg) was resolved using sodium dodecyl sulfate-polyacrylamide gel electropheresis and transferred to polyvinylidene fluoride membranes. The immunoblot was analyzed with the appropriate primary antibodies (rabbit anti-mouse antibodies against tyrosine hydroxylase (TH), MEF2D, glycogen synthase kinase-3β (GSK3β), β-actin; 1:1,000) at 4°C overnight. Horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (1:2,500) at room temperature for 2 hours were used to detect the proteins of interest through enhanced chemiluminescence. All primary and secondary antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Quantitative assessment of protein bands by densitometry was done with Gel Doc? XRS equipped with Quantity One software (Bio-Rad, Hercules, CA, USA).

    Activity of MAO-B inhibition

    MAO-B activity was determined by MAO-GloTM Assay kit (Promega, Sunnyvale, CA, USA). The recombinant human MAO-B enzyme was purchased from Sigma-Aldrich. Briefly, B3C (1 μM-10 mM) and rasagiline (10 pM-10 μM) were incubated in 96-well opaque white plates with MAO substrate and recombinant human MAO-B (0.25 mg protein/mL). Reaction was started by the addition of recombinant human MAO-B. Reaction mixture was incubated for 1 hour at room temperature. Reaction was terminated by the addition of luciferin detection reagent, and sample was incubated for an additional 20 minutes to allow the development of luciferase-dependent luminescence. Relative luminescence was determined by a plate luminometer (BioTek, Winooski, VT, USA). Results were presented as the percent of vehicle (total MAO-B activity).

    Statistical analysis

    All data are expressed as the mean ± SEM and analyzed using GraphPad Prism 5.0 (GraphPad, San Diego, CA, USA). One-way analysis of variance and Dunnett’s test were used to evaluate the statistical differences. A value of P < 0.05 was considered statistically significant.

    Results

    The effects of B3C and/or rasagiline on behavioral abnormities induced by MPTP in mice

    MPTP injection significantly induced motor abnormalities, including postural rigidity, impaired balance and coordination and gait disorder in mice. At 15thday after MPTP injection, the latency in the catalepsy test was increased by 4.8-fold (Figure 2A), the time staying on the rotarod was decreased by 57.7% (Figure 2B), and the duration of pole test was increased by 3.1 times in the MPTP-treated mice, compared to the control mice (Figure 2C). In footprint test, the time taken to cross the corridor was significantlyextended, accompanying increased step width and decreased stride length in the MPTP-treated mice, compared to the control mice (Figure 2D-F). B3C and rasagiline alone or their combination alleviated motor abnormities induced by MPTP (P < 0.05; Figure 2). Besides, neither rasagiline alone nor B3C+rasagiline co-treatment significantly reversed MPTP-induced behavioral abnormity in the rotarod test (P > 0.05; Figure 2B). In addition, there was no significant difference among B3C, rasagiline, and their combination on the reversion of motor abnormities in catalepsy, pole and footprint tests (P > 0.05).

    Figure 2 B3C, rasagiline and their combination alleviated MPTP-induced behaviour abnormities in mice.

    Figure 1 Chemical structures of bis(propyl)-cognitin (B3C) and rasagiline.

    The effects of B3C and/or rasagiline on contents of dopamine and its metabolites in the striatum of MPTP-injected mice

    Representative HPLC chromatographic peaks of dopamine and its metabolites were shown in Figure 3A. Striatal dopamine, DOPAC and HVA were significantly reduced inMPTP-treated mice when compared to control (P < 0.05; Figure 3B-D). B3C, rasagiline and their combination increased the levels of dopamine and its metabolites when compared to the MPTP group (P < 0.05). However, there was no significant difference among B3C, rasagiline and their combination (P > 0.05).

    Figure 3 B3C, rasagiline and their combination reduced MPTP-induced decrease of dopamine and its metabolites in mice.

    Figure 4 B3C, rasagiline and their combination reversed MPTP-induced decrease of TH expression in the substantia nigra (western blot assay).

    The effects of B3C and/or rasagiline on the TH expression in the substantia nigra of MPTP-injected mice

    TH was widely accepted as a marker for dopaminergic neurons (Haavik and Toska, 1998). We used western blot assay to measure the expression of TH in the substantia nigra. MPTP significantly reduced the expression of TH when compared to the control group (P < 0.05). B3C, rasagiline and their combination increased TH expression when compared to the MPTP group (P < 0.05). However, there was no significant difference among B3C, rasagiline and their combination (P > 0.05; Figure 4).

    Activities of B3C and rasagiline on MAO-B inhibition in vitro

    B3C concentration-dependently inhibited MAO-B activity with an IC50of 115.8 μM (Figure 5). Rasagiline, a wellknown selective MAO-B inhibitor, inhibited MAO-B activity with an IC50of 6.43 nM (Figure 5), which is similar to a previous report (Zheng et al., 2005).

    Regulating the expressions of GSK3β and MEF2D by B3C and/or rasagiline in the substantia nigra of MPTP-injected mice

    It was reported that MPP+could damage dopamine neurons via the inhibition of MEF2D transcriptional activity (Yao et al., 2012). MEF2D could be regulated by several signalling pathways. For example, GSK3β, an downstream molecule of PI3-K/Akt signaling pathway, could directly phosphorylate MEF2D and decrease the activity of MEF2D (Weinreb et al., 2005b; Wang et al., 2009; Yao et al., 2012). MEF2D could further protect dopamine neurons in the substantia nigra against neurotoxicity in PD animal models (Smith et al., 2006; She et al., 2011). In this study, MPTP signficanlty down-regulated the expression of MEF2D, while up-regulated the expression of GSK3β in the substantia nigra (P < 0.05; Figure 6). B3C, but not rasagiline or their combination, significantly reversed MPTP-induced alteration of GSK3β and MEF2D (P < 0.05; Figure 6).

    Discussion

    In the past decade, none of mono-drug therapies aimed to treat PD with disease-modifying potential was successful in clinical trials (Kalia et al., 2015). The multiple disease etiologies implicated in PD gave rise to a shift from a single-target to a multi-target therapy (NINDS NET-PD Investigators, 2006, 2007; Reznichenko et al., 2010).

    It has been reported that continuous administration of rasagiline (0.05 mg/kg, oral administration) following MPTP lesion restored the loss of dopaminergic neurons, the decrease of striatal dopamine content, and the reduction of TH activity (Mandel et al., 2007). Therefore, rasagiline at 0.02 and 0.1 mg/kg was used in the present study. In our study, rasagiline at both dosages was effective to treat MPTP-induced Parkinsonism, while the higher dosage did not exert greater neuroprotection. Similar results were reported by Sagi et al. (2007), showing that doubling the dose of rasagiline to 0.1 mg/kg did not lead to the greater neuroprotection. It was demonstrated that rasagiline could not produce neuroprotection at very high doses (0.25-1 mg/kg) (Sagi et al., 2007). The molecular mechanism underlying the neuroprotection of rasagiline involved the increase of protein kinase Cε, the activation of mitogen-activated protein kinase pathway, and the induction of neurotrophic factors (Yogev-Falach et al., 2003; Bar-Am et al., 2005; Weinreb et al., 2005a).

    B3C (1 mg/kg) reversed MPTP-induced loss of dopaminergic neurons and behavioral abnormitiies via effectively up-regulating MEF2D from the activation of Akt/GSK3β pathway (Yao et al., 2012). In the present study, 0.3 and 1 mg/kg B3C also alleviated behavioural abnormitiies, restored the contents of dopamine and its metabolites in the striatum, and up-regulated TH expression in the substantia nigra. To examine whether the effectiveness of B3C is associated with MAO inhibition, we have performed MAO-B activity assay. Our results showed that B3C could inhibit MAO-B with an IC50of 115.8 μM. However, B3C could effectively prevent glutamate and K+deprivation-induced neurotoxicity with an IC50at sub-nanomolar level (Luo et al., 2010; Hu et al., 2013). The concentration up to 100 μM is toxic to neurons and cannot be reached in the brain when 1 mg/kg of B3C was administrated to mice. Therefore, we deduced that the neuroprotective effects of B3C in MPTP-injected mice were independent of its MAO-B inhibition property. In consistent with the findings of a previous study (Yao et al., 2012), B3C up-regulated MEF2D and inhibited GSK3β in our study. However, rasagiline and the combination of B3C and rasagiline could not significantly alter the expressions of MEF2D and GSK3β. How could rasagiline counteract the effect of B3C on the expression of MEF2D and GSK3β? It needs to be investigated in our further study.

    The reason why there is no synergism between B3C and rasagiline is possibly due to the concentrations of drugs used in the present study. In the study of Reznichenko et al. (2010), to test the additive/synergistic action of the combination of rasagiline and EGCG in MPTP mice, low/sub-effective dosages of drugs were chosen. And individual drug at used dosage did not exert positive effects. Such experimental design could circumvent potential “masking” of the contribution of rasagiline and EGCG to the neuroprotective effects. In our study, the dosages of B3C and rasagiline were close to their maximal effective dosages. Therefore, low/sub-effective dosages are required for further investigating the synergism between B3C and rasagiline on MPTP-induced model of Parkinsonism.

    In the present study, we have investigated, for the first time, the synergistic effects between B3C and rasagiline in MPTP-induced mice model of Parkinsonism. In consistent with previous findings (Mandel et al., 2007; Sagi et al., 2007; Yao et al., 2012), both B3C and rasagiline significantly protected dopaminergic neurons against damage and reversed behavioral abnormities in MPTP-treated mice. However, the combination of B3C and rasagiline could not produce synergistic effects.

    Author contributions: ZJZ, YFH and SMYL designed the study. ZJZ and YQW wrote and revised the paper. CYZ and WC1 performed experiments and analyzed experimental data. BJG, WC2 and SHM participated in study design and performed experiments. All authors approved the final version of the paper.

    Conflicts of interest: None declared.

    Plagiarism check: This paper was screened twice using Cross-Check to verify originality before publication.

    Peer review: This paper was double-blinded and stringently reviewed by international expert reviewers.

    References

    Ahlskog JE, Uitti RJ (2010) Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction? Neurology 74:1143-1148.

    Bao XQ, Kong XC, Qian C, Zhang D (2012) FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson’s disease models. Neuroscience 202:396-404.

    Bar-Am O, Weinreb O, Amit T, Youdim MBH (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19:1899-1901.

    Figure 5 B3C and rasagiline inhibit MAO-B activity in vitro.

    Figure 6 B3C, rasagiline and their combination reversed MPTP-induced alteration of MEF2D and GSK3β expressions in the substantia nigra (western blot assay).

    Calabresi P, Di Filippo M (2015) Multitarget disease-modifying therapy in Parkinson’s disease? Lancet Neurol 14:975-976.

    Carlier PR, Han YF, Chow ES, Li CP, Wang H, Lieu TX, Wong HS, Pang YP (1999) Evaluation of short-tether Bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Biorg Med Chem 7:351-357.

    Degli Esposti L, Piccinni C, Sangiorgi D, Nobili F, Buda S (2015) Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurol Sci 37:227-234.

    Haavik J, Toska K (1998) Tyrosine hydroxylase and Parkinson’s disease. Mol Neurobiol 16:285-309.

    Han RW, Zhang RS, Chang M, Peng YL, Wang P, Hu SQ, Choi CL, Yin M, Wang R, Han YF (2012) Reversal of scopolamine-induced spatial and recognition memory deficits in mice by novel multifunctional dimers bis-cognitins. Brain Res 1470:59-68.

    Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neurosci 24:2045-2053.

    Hu SQ, Cui W, Xu DP, Mak SH, Tang J, Choi CL, Pang YP, Han YF (2013) Substantial neuroprotection against K+deprivation-induced apoptosis in primary cerebellar granule neurons by novel dimer bis(propyl)-cognitin via the activation of VEGFR-2 signaling pathway. CNS Neurosci Ther 19:764-772.

    Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2:141-151.

    Jeanjean A, Aubert G (2011) Moving pictures of Parkinson’s disease. Lancet 378:1773-1774.

    Kalia LV, Kalia SK, Lang AE (2015) Disease-modifying strategies for Parkinson’s disease. Mov Disord 30:1442-1450.

    Luo J, Li W, Zhao Y, Fu H, Ma DL, Tang J, Li C, Peoples RW, Li F, Wang Q, Huang P, Xia J, Pang Y, Han Y (2010) Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis(propyl)-cognitin. J Biol Chem 285:19947-19958.

    Mandel SA, Sagi Y, Amit T (2007) Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res 32:1694-1699.

    Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10:377-393.

    Naoi M, Maruyama W, Inaba-Hasegawa K (2013) Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother 13:671-684.

    NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664-671.

    NINDS NET-PD Investigators (2007) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:20-28.

    Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50:435-441.

    Reznichenko L, Kalfon L, Amit T, Youdim MB, Mandel SA (2010) Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. Neurodegener Dis 7:219-231.

    Richter F, Hamann M, Richter A (2007) Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J Neurosci Res 85:681-691.

    Sagi Y, Mandel S, Amit T, Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25:35-44.

    Schapira AH (2004) Disease modification in Parkinson’s disease. Lancet Neurol 3:362-368.

    Sedelis M, Schwarting RK, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav Brain Res 125:109-125.

    She H, Yang Q, Shepherd K, Smith Y, Miller G, Testa C, Mao Z (2011) Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest 121:930-940.

    Smith K (2010) Treatment frontiers. Nature 466:S15-S18.

    Smith PD, Mount MP, Shree R, Callaghan S, Slack RS, Anisman H, Vincent I, Wang X, Mao Z, Park DS (2006) Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26:440-447.

    Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30:666-672.

    Wang X, She H, Mao Z (2009) Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. J Biol Chem 284:32619-32626.

    Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005a) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathwa. Ann N Y Acad Sci 1053:348-355.

    Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005b) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 1053:348-355.

    Yao L, Li W, She H, Dou J, Jia L, He Y, Yang Q, Zhu J, Cápiro NL, Walker DI, Pennell KD, Pang Y, Liu Y, Han Y, Mao Z (2012) Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. J Biol Chem 287:34246-34255.

    Yogev-Falach M, Amit T, Bar-Am O, Youdim MB (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17:2325-2327.

    Youdim MBH, Wadia A, Tatton W, Weinstock M (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939:450-458.

    Zhang Z, Lai D, Wang L, Yu P, Zhu L, Guo B, Xu L, Zhou L, Sun Y, Lee SM, Wang Y (2014) Neuroprotective effects of the andrographolide analogue AL-1 in the MPP+/MPTP-induced Parkinson’s disease model in vitro and in mice. Pharmacol Biochem Behav 122:191-202.

    Zhang Z, Li G, Szeto SS, Chong CM, Quan Q, Huang C, Cui W, Guo B, Wang Y, Han Y, Michael Siu KW, Yuen Lee SM, Chu IK (2015) Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease. Free Radic Biol Med 84:331-343.

    Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95:68-78.

    Copyedited by Yu J, Qiu Y, Li CH, Song LP, Zhao M

    10.4103/1673-5374.189201

    *Correspondence to:

    成人三级做爰电影| 亚洲成人久久性| 亚洲成人精品中文字幕电影| 琪琪午夜伦伦电影理论片6080| 国产精品久久视频播放| 亚洲第一电影网av| av福利片在线观看| 久久久国产欧美日韩av| 亚洲av第一区精品v没综合| 很黄的视频免费| 窝窝影院91人妻| 亚洲 欧美 日韩 在线 免费| 波多野结衣高清作品| 久久精品91无色码中文字幕| 国产综合懂色| 欧美日韩黄片免| 国产精品一及| 久久久色成人| 人妻丰满熟妇av一区二区三区| 日本成人三级电影网站| 男女做爰动态图高潮gif福利片| 一个人免费在线观看电影 | www日本在线高清视频| 成人国产一区最新在线观看| 最近视频中文字幕2019在线8| 一进一出抽搐动态| 99久久精品一区二区三区| 国产99白浆流出| 免费av毛片视频| 色播亚洲综合网| 老司机午夜福利在线观看视频| 在线国产一区二区在线| 午夜福利18| 亚洲av电影在线进入| 成人性生交大片免费视频hd| 亚洲 欧美一区二区三区| 动漫黄色视频在线观看| 老汉色av国产亚洲站长工具| 热99re8久久精品国产| 啦啦啦韩国在线观看视频| 午夜福利在线观看免费完整高清在 | 欧美极品一区二区三区四区| h日本视频在线播放| 国产一区在线观看成人免费| a级毛片在线看网站| 欧美极品一区二区三区四区| 国产精品亚洲一级av第二区| 男女床上黄色一级片免费看| 真人一进一出gif抽搐免费| 国产综合懂色| 日韩中文字幕欧美一区二区| 九色成人免费人妻av| 真人一进一出gif抽搐免费| 淫妇啪啪啪对白视频| 动漫黄色视频在线观看| 亚洲av成人av| 久久这里只有精品19| 亚洲av中文字字幕乱码综合| 成人国产一区最新在线观看| 亚洲精品中文字幕一二三四区| 亚洲精品456在线播放app | 最近最新免费中文字幕在线| 亚洲男人的天堂狠狠| 日韩精品中文字幕看吧| 欧美午夜高清在线| 久久久国产成人免费| 99热精品在线国产| 午夜免费成人在线视频| 91在线精品国自产拍蜜月 | 曰老女人黄片| 最新中文字幕久久久久 | 欧美乱码精品一区二区三区| 啦啦啦免费观看视频1| 国产高清有码在线观看视频| 欧美中文综合在线视频| 动漫黄色视频在线观看| 九九热线精品视视频播放| 国产成人一区二区三区免费视频网站| 香蕉久久夜色| 啦啦啦免费观看视频1| 日韩av在线大香蕉| xxx96com| 日本黄大片高清| 偷拍熟女少妇极品色| 在线看三级毛片| 欧美日本视频| 日韩成人在线观看一区二区三区| 91久久精品国产一区二区成人 | 久久久精品大字幕| 三级国产精品欧美在线观看 | 熟妇人妻久久中文字幕3abv| 久久精品aⅴ一区二区三区四区| 中亚洲国语对白在线视频| 久久伊人香网站| 午夜两性在线视频| 亚洲av免费在线观看| 久久久色成人| 国产精品亚洲美女久久久| 欧美av亚洲av综合av国产av| 国模一区二区三区四区视频 | 久久久久久大精品| 熟女少妇亚洲综合色aaa.| 成年版毛片免费区| 国产av不卡久久| bbb黄色大片| 色综合婷婷激情| 亚洲自拍偷在线| 最近最新中文字幕大全免费视频| 熟女少妇亚洲综合色aaa.| 三级男女做爰猛烈吃奶摸视频| 香蕉av资源在线| 亚洲成av人片免费观看| 韩国av一区二区三区四区| 亚洲成人精品中文字幕电影| 久久亚洲真实| 亚洲av成人精品一区久久| 成人av一区二区三区在线看| a级毛片a级免费在线| 两人在一起打扑克的视频| 在线十欧美十亚洲十日本专区| 色噜噜av男人的天堂激情| 最近最新免费中文字幕在线| 国产激情偷乱视频一区二区| 中文字幕人成人乱码亚洲影| 成年人黄色毛片网站| 日日摸夜夜添夜夜添小说| 欧美又色又爽又黄视频| 精品久久久久久久末码| 精品国内亚洲2022精品成人| 久久久国产欧美日韩av| 又大又爽又粗| 久久精品国产综合久久久| 成人三级黄色视频| 青草久久国产| 亚洲国产日韩欧美精品在线观看 | 国产黄色小视频在线观看| 99久国产av精品| 国产精品一区二区精品视频观看| 久久香蕉国产精品| 精品久久久久久成人av| 老熟妇仑乱视频hdxx| 最近视频中文字幕2019在线8| 成年女人毛片免费观看观看9| 欧美不卡视频在线免费观看| 一二三四社区在线视频社区8| 99热6这里只有精品| 无限看片的www在线观看| 一区福利在线观看| 狂野欧美白嫩少妇大欣赏| 国产午夜精品论理片| 一a级毛片在线观看| 桃红色精品国产亚洲av| 欧美日本视频| 日韩欧美一区二区三区在线观看| 狂野欧美白嫩少妇大欣赏| 免费看光身美女| 18禁国产床啪视频网站| 久99久视频精品免费| 一本综合久久免费| 亚洲18禁久久av| 99热6这里只有精品| 亚洲午夜精品一区,二区,三区| 91麻豆精品激情在线观看国产| 别揉我奶头~嗯~啊~动态视频| 国产成+人综合+亚洲专区| 国产主播在线观看一区二区| 狂野欧美白嫩少妇大欣赏| 亚洲va日本ⅴa欧美va伊人久久| 黄色女人牲交| 亚洲成a人片在线一区二区| 欧美日韩精品网址| 露出奶头的视频| 成人三级做爰电影| 又粗又爽又猛毛片免费看| 岛国在线免费视频观看| 亚洲av中文字字幕乱码综合| 色综合亚洲欧美另类图片| 最近在线观看免费完整版| 亚洲无线观看免费| 十八禁网站免费在线| 国产日本99.免费观看| 黄色日韩在线| 免费看美女性在线毛片视频| 精品国产乱子伦一区二区三区| 国产av在哪里看| 精品久久久久久久末码| 搡老熟女国产l中国老女人| 国产伦精品一区二区三区视频9 | 丰满人妻熟妇乱又伦精品不卡| 每晚都被弄得嗷嗷叫到高潮| 免费搜索国产男女视频| 99久久99久久久精品蜜桃| 久久精品国产亚洲av香蕉五月| av女优亚洲男人天堂 | 性色avwww在线观看| 在线国产一区二区在线| 99精品欧美一区二区三区四区| 亚洲欧美激情综合另类| 在线a可以看的网站| 淫秽高清视频在线观看| 99久久成人亚洲精品观看| 国产三级中文精品| 午夜福利视频1000在线观看| 国产精品一区二区三区四区免费观看 | 天堂√8在线中文| 欧美中文日本在线观看视频| 亚洲精品在线美女| 黄色视频,在线免费观看| 伦理电影免费视频| 欧美在线黄色| 久久久久性生活片| 99视频精品全部免费 在线 | 国产精品99久久99久久久不卡| 国产三级黄色录像| 日韩欧美在线二视频| 国内少妇人妻偷人精品xxx网站 | 又粗又爽又猛毛片免费看| 老鸭窝网址在线观看| 成人一区二区视频在线观看| 午夜福利欧美成人| 日本撒尿小便嘘嘘汇集6| 精品不卡国产一区二区三区| av视频在线观看入口| 天堂网av新在线| 国产成人系列免费观看| 精品欧美国产一区二区三| 搞女人的毛片| 色综合站精品国产| 日韩欧美一区二区三区在线观看| 久久这里只有精品19| 在线a可以看的网站| 国产精品精品国产色婷婷| 真实男女啪啪啪动态图| 色噜噜av男人的天堂激情| 女警被强在线播放| 色哟哟哟哟哟哟| 岛国在线免费视频观看| 真人做人爱边吃奶动态| 亚洲激情在线av| 成人鲁丝片一二三区免费| 亚洲 欧美 日韩 在线 免费| 最近最新免费中文字幕在线| 亚洲国产精品合色在线| 99国产综合亚洲精品| 精品一区二区三区av网在线观看| 国产伦精品一区二区三区视频9 | 国产久久久一区二区三区| 亚洲av成人不卡在线观看播放网| 香蕉国产在线看| 久久久久国产精品人妻aⅴ院| 19禁男女啪啪无遮挡网站| 日本在线视频免费播放| 国产男靠女视频免费网站| 黄片大片在线免费观看| av福利片在线观看| 亚洲aⅴ乱码一区二区在线播放| 一级毛片高清免费大全| 免费电影在线观看免费观看| 亚洲avbb在线观看| 久久国产乱子伦精品免费另类| 午夜精品在线福利| 国产视频一区二区在线看| 香蕉丝袜av| 日韩大尺度精品在线看网址| 国产精品一及| 国产精品永久免费网站| 99re在线观看精品视频| 国产亚洲欧美98| 两个人的视频大全免费| 免费搜索国产男女视频| 欧美精品啪啪一区二区三区| 极品教师在线免费播放| 少妇的逼水好多| 18禁国产床啪视频网站| 高清在线国产一区| 热99在线观看视频| 久久草成人影院| 国产高清视频在线播放一区| 禁无遮挡网站| 欧美日韩综合久久久久久 | 中文字幕高清在线视频| 亚洲精品粉嫩美女一区| 免费在线观看日本一区| 美女高潮喷水抽搐中文字幕| 国产综合懂色| 欧美在线黄色| 99久国产av精品| 午夜福利在线在线| 99在线视频只有这里精品首页| 变态另类成人亚洲欧美熟女| 99国产精品一区二区蜜桃av| 搞女人的毛片| 香蕉丝袜av| 亚洲av中文字字幕乱码综合| 久久香蕉国产精品| 一级毛片精品| 波多野结衣高清作品| 在线播放国产精品三级| 久久精品aⅴ一区二区三区四区| 亚洲一区高清亚洲精品| 婷婷精品国产亚洲av在线| 亚洲欧美日韩高清专用| 精品一区二区三区视频在线观看免费| 久久久久国内视频| 亚洲欧美精品综合一区二区三区| 久久久久久久精品吃奶| 天天一区二区日本电影三级| 最近视频中文字幕2019在线8| 窝窝影院91人妻| 欧美黄色片欧美黄色片| 久久热在线av| 美女高潮喷水抽搐中文字幕| 国产在线精品亚洲第一网站| 国产91精品成人一区二区三区| 精品日产1卡2卡| 国产野战对白在线观看| 久久久久性生活片| 亚洲真实伦在线观看| 久99久视频精品免费| 999精品在线视频| 嫁个100分男人电影在线观看| 国产精品一区二区三区四区免费观看 | 欧美zozozo另类| 国产熟女xx| 久久精品综合一区二区三区| 精品久久久久久久人妻蜜臀av| 美女高潮喷水抽搐中文字幕| 国产aⅴ精品一区二区三区波| 一a级毛片在线观看| 国产成人欧美在线观看| 97人妻精品一区二区三区麻豆| 18禁黄网站禁片午夜丰满| 国产极品精品免费视频能看的| 色精品久久人妻99蜜桃| av天堂中文字幕网| 麻豆av在线久日| 成人国产综合亚洲| 亚洲aⅴ乱码一区二区在线播放| 特级一级黄色大片| 91在线精品国自产拍蜜月 | 97人妻精品一区二区三区麻豆| 国产视频内射| 国产野战对白在线观看| 少妇的丰满在线观看| 2021天堂中文幕一二区在线观| 亚洲人与动物交配视频| 亚洲精品在线观看二区| 桃色一区二区三区在线观看| 午夜影院日韩av| 亚洲人成伊人成综合网2020| 免费看a级黄色片| 三级毛片av免费| 91字幕亚洲| 久99久视频精品免费| 亚洲成人久久性| 1024手机看黄色片| 18禁观看日本| 久久这里只有精品19| 男人舔奶头视频| 99久久国产精品久久久| 日本五十路高清| 很黄的视频免费| 亚洲av成人不卡在线观看播放网| 两人在一起打扑克的视频| 女人高潮潮喷娇喘18禁视频| 国产单亲对白刺激| 午夜福利欧美成人| 丰满人妻熟妇乱又伦精品不卡| 久久精品aⅴ一区二区三区四区| 熟女少妇亚洲综合色aaa.| 国产不卡一卡二| 婷婷丁香在线五月| 国产高清激情床上av| 欧美日韩亚洲国产一区二区在线观看| 久久这里只有精品中国| 国产av一区在线观看免费| 草草在线视频免费看| 国产精品 欧美亚洲| 九九久久精品国产亚洲av麻豆 | 精品久久久久久,| 女人被狂操c到高潮| 色在线成人网| 桃色一区二区三区在线观看| av国产免费在线观看| 精品久久蜜臀av无| 男人舔女人下体高潮全视频| 丰满人妻熟妇乱又伦精品不卡| 在线永久观看黄色视频| 亚洲在线自拍视频| 久久久久久久午夜电影| 91在线观看av| 黄频高清免费视频| 国产精品99久久99久久久不卡| 最近最新免费中文字幕在线| 亚洲电影在线观看av| 国产精华一区二区三区| 两个人的视频大全免费| 老司机午夜十八禁免费视频| 午夜福利18| 国产v大片淫在线免费观看| 午夜福利欧美成人| 午夜久久久久精精品| 国产91精品成人一区二区三区| 男女那种视频在线观看| АⅤ资源中文在线天堂| 人人妻人人看人人澡| 99国产综合亚洲精品| 老司机深夜福利视频在线观看| 国产黄色小视频在线观看| 成人鲁丝片一二三区免费| 亚洲国产精品sss在线观看| 人妻久久中文字幕网| 久久亚洲精品不卡| 国产又黄又爽又无遮挡在线| 波多野结衣高清作品| 国产精品野战在线观看| 极品教师在线免费播放| 欧美不卡视频在线免费观看| 午夜免费激情av| 麻豆久久精品国产亚洲av| 熟女人妻精品中文字幕| 日韩成人在线观看一区二区三区| 国产成人啪精品午夜网站| 久久精品国产清高在天天线| 免费观看精品视频网站| 最近视频中文字幕2019在线8| 国产免费男女视频| 老鸭窝网址在线观看| 熟女电影av网| 成人av在线播放网站| 好男人电影高清在线观看| e午夜精品久久久久久久| 搡老岳熟女国产| 国产久久久一区二区三区| 美女黄网站色视频| 一级毛片高清免费大全| 亚洲欧美一区二区三区黑人| 精品不卡国产一区二区三区| 精品熟女少妇八av免费久了| 99久久国产精品久久久| 久久精品91蜜桃| 天天躁日日操中文字幕| 日本黄色视频三级网站网址| 无人区码免费观看不卡| 五月伊人婷婷丁香| 国产 一区 欧美 日韩| 九色成人免费人妻av| 韩国av一区二区三区四区| 欧美成人性av电影在线观看| 女同久久另类99精品国产91| 久99久视频精品免费| 国产男靠女视频免费网站| 午夜福利成人在线免费观看| 久久久久久久久久黄片| 亚洲国产欧美网| 狠狠狠狠99中文字幕| 精品不卡国产一区二区三区| 熟女人妻精品中文字幕| 美女免费视频网站| 国产综合懂色| 90打野战视频偷拍视频| 婷婷亚洲欧美| 久久性视频一级片| 日本五十路高清| 精品99又大又爽又粗少妇毛片 | 看片在线看免费视频| 俄罗斯特黄特色一大片| 亚洲专区国产一区二区| 精品一区二区三区视频在线 | 亚洲九九香蕉| 国产精品99久久99久久久不卡| 久久九九热精品免费| 久久欧美精品欧美久久欧美| 老司机福利观看| 精品乱码久久久久久99久播| 人人妻人人看人人澡| 亚洲欧美日韩卡通动漫| 亚洲电影在线观看av| 国产成人aa在线观看| 美女免费视频网站| 精品久久久久久久久久免费视频| 亚洲性夜色夜夜综合| 国产乱人伦免费视频| 亚洲欧美日韩高清专用| 日韩成人在线观看一区二区三区| 中文在线观看免费www的网站| 国产av不卡久久| 成人永久免费在线观看视频| 性色avwww在线观看| 亚洲专区中文字幕在线| 人妻久久中文字幕网| 88av欧美| 美女高潮的动态| 国产v大片淫在线免费观看| 草草在线视频免费看| 中文字幕久久专区| 91av网站免费观看| 中文亚洲av片在线观看爽| 无人区码免费观看不卡| 久久亚洲精品不卡| 欧美最黄视频在线播放免费| 亚洲av第一区精品v没综合| 国产亚洲精品久久久久久毛片| 在线观看免费午夜福利视频| 亚洲成人中文字幕在线播放| 欧美一级a爱片免费观看看| 叶爱在线成人免费视频播放| 在线观看66精品国产| 国产麻豆成人av免费视频| 丁香欧美五月| 国内精品久久久久精免费| 精品国产乱码久久久久久男人| 三级男女做爰猛烈吃奶摸视频| 国产真实乱freesex| 欧美av亚洲av综合av国产av| 日本一本二区三区精品| 极品教师在线免费播放| 熟女电影av网| 日本黄色片子视频| 欧美黄色片欧美黄色片| 国产成+人综合+亚洲专区| 俺也久久电影网| 亚洲真实伦在线观看| 高清在线国产一区| 亚洲狠狠婷婷综合久久图片| 黄色成人免费大全| 99热6这里只有精品| 国产蜜桃级精品一区二区三区| 成人欧美大片| 99国产精品一区二区蜜桃av| 欧美一区二区精品小视频在线| 特大巨黑吊av在线直播| 国产黄a三级三级三级人| 亚洲最大成人中文| 亚洲国产色片| 国产精品香港三级国产av潘金莲| 国产av麻豆久久久久久久| 免费人成视频x8x8入口观看| 日韩人妻高清精品专区| 日韩欧美在线二视频| 色综合站精品国产| 久久国产精品影院| 国产视频内射| 岛国视频午夜一区免费看| 国产免费男女视频| 久久久色成人| 亚洲国产看品久久| 美女被艹到高潮喷水动态| 国产成人精品久久二区二区91| 身体一侧抽搐| 校园春色视频在线观看| 国产成人福利小说| 国产精品98久久久久久宅男小说| 精品无人区乱码1区二区| 欧美午夜高清在线| 国产精品亚洲美女久久久| 亚洲成av人片免费观看| 啦啦啦免费观看视频1| 成人一区二区视频在线观看| 母亲3免费完整高清在线观看| 嫩草影视91久久| 国产高清videossex| 床上黄色一级片| 精品福利观看| 国产日本99.免费观看| 在线免费观看的www视频| 一个人看视频在线观看www免费 | 国产成人啪精品午夜网站| 亚洲av日韩精品久久久久久密| av福利片在线观看| 夜夜夜夜夜久久久久| 99精品欧美一区二区三区四区| 亚洲欧美日韩东京热| 久9热在线精品视频| 少妇丰满av| 人人妻人人看人人澡| 午夜免费激情av| 搡老岳熟女国产| 国产欧美日韩精品一区二区| 久久天躁狠狠躁夜夜2o2o| 国产男靠女视频免费网站| 99热这里只有是精品50| 最近最新中文字幕大全免费视频| 国产乱人视频| 中文在线观看免费www的网站| 在线观看美女被高潮喷水网站 | 免费一级毛片在线播放高清视频| 精品久久久久久久末码| 亚洲乱码一区二区免费版| 91老司机精品| cao死你这个sao货| 男人舔奶头视频| 日本一本二区三区精品| 国产成人精品久久二区二区91| 又粗又爽又猛毛片免费看| 国产aⅴ精品一区二区三区波| 亚洲精品中文字幕一二三四区| 日韩人妻高清精品专区| 国产又黄又爽又无遮挡在线| а√天堂www在线а√下载| 日韩免费av在线播放| 午夜久久久久精精品| 亚洲精品中文字幕一二三四区| 大型黄色视频在线免费观看| 国产又黄又爽又无遮挡在线| 欧美成人性av电影在线观看| 97碰自拍视频| 九色国产91popny在线| 69av精品久久久久久| 女人高潮潮喷娇喘18禁视频| 高潮久久久久久久久久久不卡| 日本 欧美在线| 日韩欧美精品v在线| 国产1区2区3区精品| 桃红色精品国产亚洲av|